爱博医疗(688050) - 2022 Q1 - 季度财报

Financial Performance - Revenue for Q1 2022 reached ¥131,293,097.39, an increase of 55.54% compared to the same period last year[2] - Net profit attributable to shareholders was ¥58,690,335.27, reflecting a growth of 63.00% year-over-year[2] - Net profit excluding non-recurring gains and losses was ¥52,203,876.14, up 65.15% from the previous year[2] - Basic earnings per share were ¥0.56, representing a 64.71% increase year-over-year[2] - Total operating revenue for Q1 2022 reached ¥131,293,097.39, a significant increase of 55.5% compared to ¥84,409,414.34 in Q1 2021[14] - Net profit for Q1 2022 was ¥56,973,417.09, up 57.6% from ¥36,133,957.99 in Q1 2021[17] - Operating profit for Q1 2022 was ¥72,819,938.17, representing a 81.6% increase from ¥40,093,593.73 in Q1 2021[16] - Basic earnings per share for Q1 2022 were ¥0.56, up from ¥0.34 in Q1 2021, reflecting a growth of 64.7%[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,091,113,769.92, a 2.13% increase from the end of the previous year[3] - As of March 31, 2022, the company's total assets amounted to approximately RMB 2.09 billion, an increase from RMB 2.05 billion at the end of 2021[11] - The total liabilities decreased to ¥288,366,805.26 in Q1 2022 from ¥307,463,789.44 in Q1 2021, a reduction of 6.4%[13] - Total equity attributable to shareholders increased to ¥1,738,177,735.85 in Q1 2022 from ¥1,673,846,060.67 in Q1 2021, an increase of 3.9%[13] Cash Flow - Operating cash flow net amount was ¥40,870,536.64, increasing by 33.95% compared to the same period last year[2] - Cash inflow from operating activities was ¥125,145,372.12 in Q1 2022, compared to ¥91,571,952.81 in Q1 2021, marking a growth of 36.7%[19] - The net cash flow from operating activities was $40,870,536.64, an increase from $30,512,472.57 in the previous year[20] - The ending balance of cash and cash equivalents was $151,480,786.20, down from $298,631,687.02 year-over-year[21] - The cash and cash equivalents decreased by $321,390,731.18 during the quarter, compared to a decrease of $238,208,326.49 in the previous year[20] Research and Development - R&D investment totaled ¥14,840,254.47, accounting for 11.30% of revenue, a decrease of 5 percentage points[3] - Research and development expenses for Q1 2022 were ¥12,616,211.99, an increase of 16.3% from ¥10,846,222.20 in Q1 2021[16] - The company has developed the "Punotong-Ximing" multifunctional rigid contact lens care solution, which has obtained a Class III medical device registration certificate and production license, and is currently in the market promotion phase[9] - The non-spherical extended depth of focus (EDoF) artificial lenses are starting clinical trials within China[9] Market and Operational Challenges - The increase in revenue was primarily driven by sales growth of the "Punoming" series artificial lenses and "Punotong" corneal reshaping lenses[5] - The company reported a significant impact on business growth due to the prolonged COVID-19 pandemic affecting patient visits for cataract and myopia treatments[8] - The company is facing delays in some R&D projects due to the pandemic's impact on operations[9] Non-Recurring Items - The company reported non-recurring gains of ¥6,486,459.13 for the period[5] - Tax expenses for Q1 2022 were ¥15,978,522.60, significantly higher than ¥3,974,396.34 in Q1 2021, reflecting an increase of 302.5%[16]